en · de · es · fr · pt
faq-desk.peptides1004.com › Data › Regulatory And Analytical Context — Explained

Regulatory And Analytical Context — Explained

By Editorial Desk · published 2026-07-08 · last reviewed 2026-08-01 · Data

AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.

Regulatory and Analytical Context

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Identity and Molecular Context

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

Aod-9604 at a glance

PropertyValueNotes
Regulatory statusNot approved as a medicineStatus varies by country; prohibited in sport.
Common storage temperature2–8 °C for lyophilized powderProtect from light and moisture; follow supplier instructions.
Typical analytical methodLC-MS/MSUsed for identification and quantification in biological samples.
Purity assessmentHPLC and mass spectrometryReverse-phase HPLC is common for peptide purity.
Common synonymsAOD9604; hGH 176-191 fragmentNaming conventions differ across studies.

Notes from published material

On 10 January 1973, negotiations broke down when Kissinger demanded the release of all American POWs in North Vietnam once a peace agreement was signed, but offered no guarantees about Viet Cong prisoners being held in South Vietnam. Tho stated: "I cannot accept your proposal. I completely reject it". Tho wanted the release of all prisoners once a peace agreement was signed, which led Kissinger to say this was an unreasonable demand. Tho, who had been tortured as a young man by the French colonial police for advocating Vietnamese independence, shouted: "You have never been a prisoner. You don't understand suffering. It's unfair". Kissinger finally offered the concession that the United States would use "maximum influence" to pressure the South Vietnamese government to release all Viet Cong prisoners within sixty days of a peace agreement being signed. Thiệu once again rejected the peace agreement, only to receive an ultimatum from Nixon: "You must decide now whether you desire to continue our alliance or whether you want me to seek a settlement with the enemy which serves U.S. interests alone". Nixon told Kissinger: "Brutality is nothing. You have never seen it if this son-of-a-bitch doesn't go along, believe me". Nixon's threat served its purpose, and Thiệu reluctantly accepted the peace agreement. On 23 January 1973, at 12:45 pm, Kissinger and Tho signed a peace agreement in Paris that called for the complete withdrawal of all U.S. forces from Vietnam by March in exchange for North Vietnam freeing all the U.S. POWs.

=== Test strip process === The niacin test strip is typically composed of potassium thiocyanate, chloramine-T, citric acid, and 4-Aminosalicylic acid. In the presence of citric acid, chloramine-T and potassium thiocyanate will react to form cyanogen chloride. This chemical will break apart the pyridine ring of niacin to produce y-carboxy glutaconic aldehyde and joins an aromatic amine to form a yellow color.

=== Reactivity control === Chemoselectivity ensures that a specific functional group in a molecule reacts while others remain unaffected. Protecting groups temporarily mask reactive sites to enable selective reactions. Kinetic control prioritizes reaction pathways that form products quickly, often yielding less stable compounds. In contrast, thermodynamic control favors the formation of the most stable products.

Smoking or vaporizing: Using these methods, rather than injecting, is thought to reduce the risk of infections, since the high temperatures involved are more likely to kill bacteria and spores. Grinding into a powder form for snorting: This is one of the more popular ways of consuming black tar for those who do not wish to use needles. The black tar heroin is put into some sort of blender and mixed in with lactose. This creates a fine black powder product that can be easily snorted. Water looping: Water looping is when a user places the heroin in an empty eye dropper bottle, or a syringe with the needle removed. The user allows the heroin to completely dissolve into water and the solution is dropped into the nose. This at times can be wasteful if a user allows too much of the solution to go down the throat. Drinking: This is done similar to the water looping method. Instead of being delivered through the nose, the solution is swallowed. Suppository: The most effective route of administration which does not require a needle, is accomplished by delivering a solution (via syringe) or lubricated mass of the narcotic deep into the rectum or vagina.

Sources: en.wikipedia.org

Related pages on this site

Background from the literature

=== Radiography === Radiographs of the abdomen commonly show hepatomegaly. Hepatomegaly is not exclusive to hypersomatotropism and is seen in diabetic cats without hypersomatotropism. Other possible findings are renomegaly and on rare occasions splenomegaly. Thoracic radiographs can reveal cardiomegaly, pulmonary oedema, and, if affected by congestive heart failure, pleural effusion. Radiographs of bones—including the skull and spine—may reveal: increase of soft tissue around the oropharynx, mandible enlargement, hyperostosis of the calvarium and nasal bone, degenerative arthropathy of the joints, and spondylosis deformans.

== History == A scientific article published in March 2018 proposed a revision of the anatomical definition of the submucosa. They first saw a non compact tissue which should be submucosa using a technology called endomicroscopy. They hypothesised that the submucosa was not compact as it was previously seen on histological analysis but form a reticular pattern. To confirm their findings, they performed fixed samples of bile duct into a freezing media in order to conserve the shape of the submucosa. They then performed a histological analysis and with several staining techniques, they described the submucosa as a network of collagenous bands separating open, formerly fluid-filled spaces. Theses spaces are bordered by fibroblast-like cells CD34 positive. However, these cells are devoid of ultrastructural features indicative of endothelial differentiation, including pinocytotic vesicles and Weibel-Palade bodies.

Stupor: absence of psycho-motor activity; not actively relating to the environment Catalepsy: passive induction of a posture held against gravity Waxy flexibility: maintaining positions imposed by the examiner Mutism: minimal or absent verbal response (not due to aphasia) Negativism: resistance or lack of response to instructions or external stimuli Posturing: spontaneous and active maintenance of a posture against gravity Mannerisms: odd or exaggerated caricatures of normal actions Stereotypy: repetitive, abnormally frequent, non-goal-directed movements Agitation: excessive activity not influenced by external stimuli Grimacing: sustained facial expression Echolalia: mimicking another's speech Echopraxia: mimicking another's movements Other disorders (additional code 293.89 [F06.1] to indicate the presence of the co-morbid catatonia):

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 approved for medical use?

No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.

Why is it banned in sports?

The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.

How is AOD-9604 detected?

Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.

Is AOD-9604 the same as human growth hormone?

No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.

Network